---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-132481"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2024-12-30T23:59:59+00:00"
generated_at: "2026-05-28T22:40:10.221822+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics effects 1-for-12 reverse stock split and reduces authorized shares from 200M to ~16.7M

## Summary
- Effective 5:00 p.m. ET Dec 30, 2024; trading on split-adjusted basis begins Dec 31, 2024.
- Authorized common shares reduced from 200,000,000 to 16,666,667; par value unchanged.
- No fractional shares issued; cash payment will be made in lieu of fractional shares.
- Proportionate adjustments made to stock options, equity plan reserves, and exercise prices.
- Stockholder-approved at June 4, 2024 annual meeting; board approved specific ratio Dec 19, 2024.

## SEC filing metadata
- accession: 0001104659-24-132481
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2024-12-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465924132481/0001104659-24-132481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465924132481/tm2430195d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-132481
- JSON: https://secwatch.observer/filing/0001104659-24-132481.json
- Plain text: https://secwatch.observer/filing/0001104659-24-132481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.